Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.49 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | DHPS | P49366 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169059 | 0.93 | ESR1 (0.56) | ESR1BTKNR1H4PPARGPPARA | |
| SCHEMBL6171357 | 0.86 | ESR1 (0.53) | ESR1BTKNR1H4PPARGPPARA | |
| SCHEMBL6169988 | 0.85 | MAP4K4 (0.53) | BTKF10NR1H4PPARGPPARA | |
| SCHEMBL6172764 | 0.85 | NR1H4 (0.64) | ESR1BTKNR1H4PPARGPPARA | |
| SCHEMBL13483891 | 0.84 | ESR1 (0.76) | ESR1BTKDHPS | |
| SCHEMBL6170045 | 0.82 | ESR1 (0.54) | ESR1BTKNR1H4PPARGPPARA | |
| SCHEMBL7366501 | 0.82 | F10 (0.47) | F10NR1H4PPARGPPARA | |
| SCHEMBL6168843 | 0.81 | ESR1 (0.53) | ESR1BTKNR1H4PPARGPPARA | |
| SCHEMBL5226932 | 0.81 | NR1H4 (0.57) | F10NR1H4PPARGPPARA | |
| SCHEMBL5228051 | 0.80 | RAB9A (0.70) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6372759-B1 | BLOOD COAGULATION FACTOR XA FOR MAMMALS | ELI LILLY AND COMPANY | 2002-04-16 | — | — | US | claimed |
| EP-1019045-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20030078431-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2003-04-24 | — | — | US | disclosed |
| US-6500851-B2 | ANTICOAGULANT IN MAMMLS | ELI LILLY AND COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-20020173518-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-11-21 | — | — | US | disclosed |
| EP-1019045-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6372759-B1 | BLOOD COAGULATION FACTOR XA FOR MAMMALS | ELI LILLY AND COMPANY | 2002-04-16 | — | — | US | disclosed |
| EP-1019045-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999000128-A9 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1999000128-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173518-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | ESR1 4237/4885BTK 211/4885F10 15/4885 |
| US-20030078431-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | ESR1 4237/4885BTK 211/4885F10 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.